Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 10/20 | 0.64 |
| ▸ | CHUK | O15111 | 10/20 | 0.64 |
| ▸ | IKBKG | Q9Y6K9 | 10/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.54 |
| ▸ | JAK1 | P23458 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.52 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247959 | 0.99 | IKBKB (0.63) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL14063722 | 0.93 | IKBKB (0.56) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL14021292 | 0.93 | IKBKB (0.56) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL8312503 | 0.91 | IKBKB (0.56) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL8312320 | 0.90 | IKBKB (0.53) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL14021190 | 0.90 | MTOR (0.60) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL11924733 | 0.90 | MTOR (0.60) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL8254568 | 0.89 | JAK2 (0.55) | IKBKBCHUKIKBKGMEN1RECQL | |
| SCHEMBL14021219 | 0.89 | PIK3CA (0.58) | IKBKBCHUKIKBKGJAK2JAK1 | |
| SCHEMBL11924743 | 0.88 | GRM5 (0.60) | IKBKBCHUKIKBKGMEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| EP-1827422-A2 | JNK INHIBITORS FOR THE TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006058007-A2 | JNK INHIBITORS FOR TREATMENT OF CNS INJURY | CELGENE CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | IKBKB 110/4885CHUK 58/4885IKBKG 182/4885 |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | IKBKB 755/4885CHUK 433/4885IKBKG 1907/4885 |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | PGF, ALPP, CPA1 | IKBKB 2300/4885CHUK 2428/4885IKBKG 2374/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | IKBKB 89/4885CHUK 44/4885IKBKG 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.